MyD88 and TLR9 dependent immune responses mediate resistance to Leishmania guyanensis infections, irrespective of Leishmania RNA virus burden

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Ives, Annette ^a   Masina, Slavica ^a   Castiglioni, Patrik ^a   Prével, Florence ^a   Revaz Breton, Mélanie ^b   Hartley, Mary Anne ^a   Launois, Pascal ^b   Fasel, Nicolas ^a   Ronet, Catherine ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADAPTOR PROTEIN; DOUBLE STRANDED DNA; INTERLEUKIN 12; INTERLEUKIN 12P40; INTERLEUKIN 13; INTERLEUKIN 4; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 9; VIRUS DNA; INTERLEUKIN 12P35;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE EXACERBATION; IMMUNE RESPONSE; IMMUNOREGULATION; INFECTION RESISTANCE; INFECTION SENSITIVITY; INFLAMMATION; INNATE IMMUNITY; KNOCKOUT MOUSE; LEISHMANIA RNA VIRUS; LEISHMANIASIS; MOUSE; NONHUMAN; PROTEIN FUNCTION; RNA VIRUS; SIGNAL TRANSDUCTION; TH1 CELL; TH2 CELL; VIRUS LOAD; ANIMAL; C57BL MOUSE; DEFICIENCY; DISEASE PREDISPOSITION; GENETICS; IMMUNOLOGY; LEISHMANIA; LYMPH NODE; METABOLISM; PATHOLOGY; PHYSIOLOGY; SKIN LEISHMANIASIS; VETERINARY; VIROLOGY;

ANIMALS; DISEASE SUSCEPTIBILITY; IMMUNITY, INNATE; INTERLEUKIN-12 SUBUNIT P35; INTERLEUKIN-12 SUBUNIT P40; INTERLEUKIN-13; INTERLEUKIN-4; LEISHMANIA GUYANENSIS; LEISHMANIASIS, MUCOCUTANEOUS; LYMPH NODES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; RNA VIRUSES; SIGNAL TRANSDUCTION; TH1 CELLS; TH2 CELLS; TOLL-LIKE RECEPTOR 9;

EID: 84900424725     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096766     Document Type: Article

References (31)

1. Weigle K, Saravia NG (1996) Natural history, clinical evolution, and the host-parasite interaction in New World cutaneous Leishmaniasis. Clin Dermatol 14: 433-450. (Pubitemid 26327737)
2. Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC (2008) Mucosal leishmaniasis. Current scenario and prospects for treatment. Acta Trop 105: 1-9. (Pubitemid 350262798)
3. Ives A, Ronet C, Prevel F, Ruzzante G, Fuertes-Marraco S, et al. (2011) Leishmania RNA virus controls the severity of mucocutaneous leishmaniasis. Science 331: 775-778.
4. Faria DR, Gollob KJ, Barbosa J, Jr., Schriefer A, Machado PR, et al. (2005) Decreased in situ expression of interleukin-10 receptor is correlated with the exacerbated inflammatory and cytotoxic responses observed in mucosal leishmaniasis. Infect Immun 73: 7853-7859. (Pubitemid 41740268)
5. Gaze ST, Dutra WO, Lessa M, Lessa H, Guimaraes LH, et al. (2006) Mucosal leishmaniasis patients display an activated inflammatory T-cell phenotype associated with a nonbalanced monocyte population. Scand J Immunol 63: 70-78.
6. Pirmez C, Yamamura M, Uyemura K, Paes-Oliveira M, Conceicao-Silva F, et al. (1993) Cytokine patterns in the pathogenesis of human leishmaniasis. J Clin Invest 91: 1390-1395. (Pubitemid 23127337)
7. Vargas-Inchaustegui DA, Hogg AE, Tulliano G, Llanos-Cuentas A, Arevalo J, et al. (2010) CXCL10 production by human monocytes in response to Leishmania braziliensis infection. Infect Immun 78: 301-308.
8. Cabrera M, Shaw MA, Sharples C, Williams H, Castes M, et al. (1995) Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 182: 1259-1264.
9. Castellucci L, Menezes E, Oliveira J, Magalhaes A, Guimaraes LH, et al. (2006) IL6-174 G/C promoter polymorphism influences susceptibility to mucosal but not localized cutaneous leishmaniasis in Brazil. J Infect Dis 194: 519-527. (Pubitemid 44162665)
10. Lara ML, Layrisse Z, Scorza JV, Garcia E, Stoikow Z, et al. (1991) Immunogenetics of human American cutaneous leishmaniasis. Study of HLA haplotypes in 24 families from Venezuela. Hum Immunol 30: 129-135.
11. Walker J, Acestor N, Gongora R, Quadroni M, Segura I, et al. (2006) Comparative protein profiling identifies elongation factor-1beta and tryparedoxin peroxidase as factors associated with metastasis in Leishmania guyanensis. Mol Biochem Parasitol 145: 254-264. (Pubitemid 43083367)
12. Scott P (2003) Development and regulation of cell-mediated immunity in experimental leishmaniasis. Immunol Res 27: 489-498.
13. Revaz-Breton M, Ronet C, Ives A, Torre YH, Masina S, et al. (2010) The MyD88 protein 88 pathway is differently involved in immune responses induced by distinct substrains of Leishmania major. Eur J Immunol 40: 1697-1707.
14. Vargas-Inchaustegui DA, Tai W, Xin L, Hogg AE, Corry DB, et al. (2009) Distinct roles for MyD88 and Toll-like receptor 2 during Leishmania braziliensis infection in mice. Infect Immun 77: 2948-2956.
15. Debus A, Glasner J, Rollinghoff M, Gessner A (2003) High levels of susceptibility and T helper 2 response in MyD88-deficient mice infected with Leishmania major are interleukin-4 dependent. Infect Immun 71: 7215-7218. (Pubitemid 37475361)
16. de Veer MJ, Curtis JM, Baldwin TM, DiDonato JA, Sexton A, et al. (2003) MyD88 is essential for clearance of Leishmania major : possible role for lipophosphoglycan and Toll-like receptor 2 signaling. Eur J Immunol 33: 2822-2831. (Pubitemid 37337148)
17. Muraille E, De Trez C, Brait M, De Baetselier P, Leo O, et al. (2003) Genetically resistant mice lacking MyD88-adapter protein display a high susceptibility to Leishmania major infection associated with a polarized Th2 response. J Immunol 170: 4237-4241. (Pubitemid 36428190)
18. Weinkopff T, Mariotto A, Simon G, Hauyon-La Torre Y, Auderset F, et al. (2013) Role of Toll-like receptor 9 signaling in experimental Leishmania braziliensis infection. Infect Immun 81: 1575-1584.
19. De Trez C, Brait M, Leo O, Aebischer T, Torrentera FA, et al. (2004) Myd88-dependent in vivo maturation of splenic dendritic cells induced by Leishmania donovani and other Leishmania species. Infect Immun 72: 824-832. (Pubitemid 38166661)
20. Carvalho LP, Petritus PM, Trochtenberg AL, Zaph C, Hill DA, et al. (2012) Lymph node hypertrophy following Leishmania major infection is dependent on TLR9. J Immunol 188: 1394-1401.
21. Liese J, Schleicher U, Bogdan C (2007) TLR9 signaling is essential for the innate NK cell response in murine cutaneous leishmaniasis. Eur J Immunol 37: 3424-3434.
22. Duthie MS, Windish HP, Fox CB, Reed SG (2011) Use of defined TLR ligands as adjuvants within human vaccines. Immunol Rev 239: 178-196.
23. Steinhagen F, Kinjo T, Bode C, Klinman DM (2011) TLR-based immune adjuvants. Vaccine 29: 3341-3355.
24. Adachi O, Kawai T, Takeda K, Matsumoto M, Tsutsui H, et al. (1998) Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9: 143-150. (Pubitemid 28361303)
25. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, et al. (2000) A Toll-like receptor recognizes bacterial DNA. Nature 408: 740-745. (Pubitemid 32015992)
26. Schulz SM, Kohler G, Schutze N, Knauer J, Straubinger RK, et al. (2008) Protective immunity to systemic infection with attenuated Salmonella enterica serovar enteritidis in the absence of IL-12 is associated with IL-23-dependent IL-22, but not IL-17. J Immunol 181: 7891-7901.
27. Martinez JE, Valderrama L, Gama V, Leiby DA, Saravia NG (2000) Clonal diversity in the expression and stability of the metastatic capability of Leishmania guyanensis in the golden hamster. J Parasitol 86: 792-799. (Pubitemid 30646595)
28. Raman VS, Bhatia A, Picone A, Whittle J, Bailor HR, et al. (2010) Applying TLR synergy in immunotherapy: implications in cutaneous leishmaniasis. J Immunol 185: 1701-1710.
29. Raman VS, Duthie MS, Fox CB, Matlashewski G, Reed SG (2012) Adjuvants for Leishmania vaccines: from models to clinical application. Front Immunol 3: 144.
30. Stacey KJ, Blackwell JM (1999) Immunostimulatory DNA as an adjuvant in vaccination against Leishmania major. Infect Immun 67: 3719-3726. (Pubitemid 29356983)
31. Rhee EG, Mendez S, Shah JA, Wu CY, Kirman JR, et al. (2002) Vaccination with heat-killed Leishmania antigen or recombinant leishmanial protein and CpG oligodeoxynucleotides induces long-term memory CD4+ and CD8+ T cell responses and protection against Leishmania major infection. J Exp Med 195: 1565-1573. (Pubitemid 34666070)